Crinetics Pharmaceuticals Inc to Host Key Opinion Leader (KOL) Webinar Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division - Analyst : Can you hear me okay?

Question: Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division - Analyst : Perfect. Two questions, and I'll do them separately. So the first question is when your acromegaly patients come in monthly today, is that only for the somatostatin analog injections? Or are there other reasons that patients need to be managed more frequently? I'm just trying to understand if there were an efficacious convenient oral available, how much do you think you could decrease the frequency that you see patients? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 08, 2023 / 4:00PM, CRNX.OQ - Crinetics Pharmaceuticals Inc to Host Key Opinion Leader (KOL) Webinar Beverly Biller Karen, why don't you take that? Karen Liebert Yes. The patients come in monthly for the injection, specifically for the injections. They do maintain regular visits with the endocrinologists either (inaudible) visit or every -- annually based where they are in their injection cycles and treatment plans. In terms of other things that they come in for, I mean, we draw their blood and will monitor IGF-1 levels while on injections. But one of the things that we've talked about as a nursing group with these oral octreotide and oral medications coming down the pike is will we lose contact with patients. We see them monthly. We look at their sort of symptoms and how they're doing on the drug, and we have a lot of contact with them when they do come in for the appointment. So having this oral, when we may not see them as frequently, sure, I think we'll lose a little bit of contact with them. As with any new drug, you sort of hold them closely and make sure that the drug is actually working and working for them and actually controlling symptoms as well as biochemical control. So other than coming in for their annual appointments or biannual appointments with their physicians, probably the most that we'll do is like monitor symptoms and maybe side effects and then draw their bloods to make sure that they're controlled on the medication. Beverly Biller And to follow up on that, I think -- I mean, it's a very good question because really what you're getting at is, could an oral agent that's well received actually decrease cost to the health care system because patients are not coming for doctors' visits so often and will it be beneficial to the patient's daily life because they're not coming to the office so often? And Karen is completely right. If we take care of patients with acromegaly, we see them only once or twice a year, and we would not be seeing them every month if they didn't need their monthly injections.